The FDA’s draft GDUFA IV Commitment Letter proposes several important enhancements to the generic drug review program for FY2028–FY2032.Key changes include shorter priority review goals, stronger pre-submission facility correspondence (PFC), Discipline Review Letters (DRLs), improved DMF–ANDA coordination, standardized data requirements, enhanced inspection pathways, and greater performance & financial transparency.
🎯 The overarching objective: fewer review cycles, faster timelines, greater predictability, and stronger early engagement between FDA and generic drug applicants.
This poster provides a quick comparison of GDUFA III vs. the proposed GDUFA IV commitments for regulatory affairs, generic drug manufacturers, and ANDA stakeholders.
📌 Follow Pharmatext for pharma regulatory updates, FDA developments, and industry insights.
🌐 www.pharmatext.co.in
GDUFAIV GDUFA FDA USFDA ANDA GenericDrugs PharmaceuticalIndustry PharmaRegulatory RegulatoryAffairs FDAUpdates GenericDrugDevelopment DMF ANDAReview PharmaceuticalRegulations DrugRegulatory PharmaUpdates USFDAUpdates PharmaIndustry Pharmatext PharmaRegulatoryAffairs
No comments:
Post a Comment